Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10646	Companies
226451	Keywords
154914	Articles
119859	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 08/19/2025 at 15:00, 10 months 7 days ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans FDA meeting to discuss crofelemer clinical program for MVID, with proof-of-concept results reducing TPN. Abstract accepted for NASPGHAN 2025 Annual Meeting in Chicago

Napo Pharmaceuticals Crofelemer MVID FDA Meeting NASPGHAN 2025 Annual Meeting
BRIEF

published on 08/14/2025 at 14:05, 10 months 12 days ago

Croissance financière et projets futurs de Jaguar Health au deuxième trimestre 2025

Stratégie Financière Jaguar Health Croissance De Mytesi Chiffre D'affaires Du Deuxième Trimestre 2025 Recherche Sur Crofelemer
BRIEF

published on 08/14/2025 at 14:05, 10 months 12 days ago

Jaguar Health's Q2 2025 Financial Growth and Future Plans

Jaguar Health Financial Strategy Q2 2025 Revenue Mytesi Growth Crofelemer Research
PRESS RELEASE

published on 08/14/2025 at 14:00, 10 months 12 days ago

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
Jaguar Health, Inc. reports 35% revenue increase in Q2 2025 for prescription & non-prescription products, including license revenue. Mytesi prescription volume up 6.5%. Crofelemer trial yields positive results

Jaguar Health Inc. FDA Meeting Crofelemer Trial Q2 2025 Revenue Mytesi Prescription Volume
BRIEF

published on 08/12/2025 at 15:05, 10 months 14 days ago

Jaguar Health annonce un webcast destiné aux investisseurs le 14 août 2025

Résultats Financiers Jaguar Health Lisa Conte Médicaments Webcast Pour Les Investisseurs
BRIEF

published on 08/12/2025 at 15:05, 10 months 14 days ago

Jaguar Health Announces Investor Webcast on August 14, 2025

Financial Results Pharmaceuticals Investor Webcast Jaguar Health Lisa Conte
PRESS RELEASE

published on 08/12/2025 at 15:00, 10 months 14 days ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
Jaguar Health, Inc. to conduct investor webcast on August 14, 2025 to review Q2 financials and corporate updates. CEO Lisa Conte presenting at Emerging Growth Conference on August 20, 2025

Investor Webcast Lisa Conte Emerging Growth Conference Jaguar Health Inc. Q2 Financials
BRIEF

published on 07/10/2025 at 14:35, 11 months 16 days ago

Jaguar Health étend son étude sur Canalevia-CA1 pour chiens

Jaguar Health Canalevia-CA1 Santé Animale Approbation De La FDA Diarrhée Du Chien
BRIEF

published on 07/10/2025 at 14:35, 11 months 16 days ago

Jaguar Health Expands Study on Canalevia-CA1 for Dogs

FDA Approval Jaguar Health Canalevia-CA1 Animal Health Dog Diarrhea
PRESS RELEASE

published on 07/10/2025 at 14:30, 11 months 16 days ago

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. in talks with animal health partners to bring Canalevia to global market for general diarrhea in dogs. CEO presents at conference to discuss updates on Canalevia-CA1

Jaguar Health Conference Canalevia Animal Health Partners General Diarrhea

Accesswire

Published on 06/26/2026 at 15:05, 8 minutes ago

Vox Royalty Sells I-80 Gold Offtake Stream
Published on 06/26/2026 at 14:05, 1 hour 8 minutes ago

SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 1 hour 13 minutes ago

Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 2 hours 13 minutes ago

Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 2 hours 28 minutes ago

Northern Dynasty Reports Oral Arguments Held

View all ACCESSWIRE

EQS Group

Published on 06/26/2026 at 14:00, 1 hour 13 minutes ago

Hong Kong celebrates surge of global enterprises driving investment and opportunities
Published on 06/26/2026 at 14:00, 1 hour 13 minutes ago

Bitcoin Group SE publishes 2025 Annual Report: Strategic realignment ensures future viability in the dynamic crypto market
Published on 06/26/2026 at 13:32, 1 hour 41 minutes ago

Porsche ranks number one in J.D. Power 2026 U.S. Initial Quality Study
Published on 06/26/2026 at 13:30, 1 hour 42 minutes ago

Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
Published on 06/26/2026 at 13:30, 1 hour 43 minutes ago

AlphaESS Unveils Expanded Energy Storage Ecosystem for Europe at Intersolar 2026

Les Echos

Published on 06/26/2026 at 14:44, 29 minutes ago

Safran information
Published on 06/26/2026 at 14:44, 29 minutes ago

Information Safran
Published on 06/26/2026 at 12:16, 2 hours 57 minutes ago

Rapport semestriel SIEHM au 30 avril 2026
Published on 06/26/2026 at 07:00, 8 hours 13 minutes ago

Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 8 hours 13 minutes ago

Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel

View all LES ECHOS COMFI WIRE